Q-omics provides the consensus-scored ENTPD2 profile across patient tissues and cancer cell-line models. ENTPD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ENTPD2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ENTPD2 RNA expression shows 14,966 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where ENTPD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENTPD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENTPD2 survival associations across molecular data types. ENTPD2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENTPD2 RNA expression–survival associations across cancer types. High ENTPD2 expression shows unfavorable associations in BLCA, LUAD and LGG, but favorable associations in KIRP, STAD and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ENTPD2 RNA expression.
This table summarizes ENTPD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ENTPD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENTPD2 shows higher tumor expression in THCA, COAD, LIHC, LUAD, LUSC and KIRC. The THCA box plot shows higher ENTPD2 RNA expression in tumor versus normal tissue (log2 FC = +1.615, t-test p < 0.001).
This table shows molecular features associated with ENTPD2 in patient tissues and cancer cell lines. In patient samples, ENTPD2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ENTPD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
